1 |
 |
Completed |
 |
Combination Iron Chelation Therapy |
Conditions: |
 |
Iron Overload;  Thalassemia |
Intervention: |
 |
Drug: Combination Iron Chelation Therapy |
 |
2 |
 |
Completed |
 |
Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency |
Condition: |
 |
Urologic Disease |
Intervention: |
 |
Drug: calcium disodium EDTA (edetate calcium disodium) |
 |
3 |
 |
Active, not recruiting |
 |
Penicillamine Chelation for Children With Lead Poisoning |
Conditions: |
 |
Lead Poisoning;  Vitamin D Deficiency |
Interventions: |
 |
Device:Â d-penicillamine; Â Drug:Â placebo |
 |
4 |
 |
Active, not recruiting |
 |
An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload |
Condition: |
 |
Transfusional Iron Overload in β-Thalassemia |
Intervention: |
 |
Drug:Â Deferasirox |
 |
5 |
 |
Active, not recruiting |
 |
Mercury Chelation to Treat Autism |
Conditions: |
 |
Autism;  Asperger’s Disorder;  Child Development Disorders, Pervasive |
Intervention: |
 |
Drug:Â DMSA |
 |
6 |
 |
Active, not recruiting |
 |
Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload |
Condition: |
 |
Transfusional Iron Overload in β-Thalassemia Major |
Intervention: |
 |
Drug:Â Deferasirox |
 |
7 |
 |
Active, not recruiting |
 |
Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload |
Condition: |
 |
Transfusional Iron Overload in Patients With Chronic Anemia |
Intervention: |
 |
Drug:Â Deferasirox |
 |
8 |
 |
Active, not recruiting |
 |
Iron-Chelating Therapy and Friedreich Ataxia |
Condition: |
 |
Friedreich Ataxia |
Intervention: |
 |
Drug: Iron chelating intervention |
 |
9 |
 |
Completed |
 |
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone |
Conditions: |
 |
Anemia (Iron-Loading);  Beta-Thalassemia;  Hematologic Diseases;  Hemoglobinopathies;  Thalassemia;  Iron Overload |
Intervention: |
 |
Drug: chelation therapy |
 |
10 |
 |
Completed |
 |
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload |
Condition: |
 |
Transfusional Iron Overload |
Intervention: |
 |
Drug:Â Deferasirox |
 |
11 |
 |
Active, not recruiting |
 |
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major |
Condition: |
 |
Beta-Thalassemia |
Intervention: |
 |
Drug:Â deferiprone |
 |
12 |
 |
Completed |
 |
CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients |
Condition: |
 |
End Stage Renal Disease |
Intervention: |
 |
 |
 |
13 |
 |
Active, not recruiting |
 |
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload |
Condition: |
 |
Transfusion-Dependent Iron Overload |
Intervention: |
 |
Drug:Â Deferasirox |
 |
14 |
 |
Active, not recruiting |
 |
Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload |
Condition: |
 |
Transfusion-Dependent Iron Overload |
Intervention: |
 |
Drug:Â Deferasirox |
 |
15 |
 |
Completed |
 |
Efficacy Study in Removing Excess Iron From the Heart |
Conditions: |
 |
Thalassemia Major;  Hemosiderosis |
Interventions: |
 |
Drug: Ferriprox (deferiprone);  Drug: Desferal (deferoxamine) |
 |
16 |
 |
Active, not recruiting |
 |
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients |
Conditions: |
 |
Myelodysplastic Syndrome;  Iron Overload |
Intervention: |
 |
Drug:Â Deferasirox |
 |
17 |
 |
Active, not recruiting |
 |
Cardiac Function in Patients With Hereditary Hemochromatosis |
Condition: |
 |
Hemochromatosis |
Intervention: |
 |
 |
 |
18 |
 |
Active, not recruiting |
 |
A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis |
Condition: |
 |
Sickle Cell Disease |
Intervention: |
 |
Drug:Â Deferasirox |
 |
19 |
 |
Active, not recruiting |
 |
Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis |
Condition: |
 |
Beta-Thalassemia Major |
Intervention: |
 |
Drug:Â ICL670;Â deferasirox |
 |
20 |
 |
Completed |
 |
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis |
Condition: |
 |
Idiopathic Pulmonary Fibrosis |
Intervention: |
 |
Drug:Â Tetrathiomolybdate |
 |
21 |
 |
Active, not recruiting |
 |
Treatment of Lead-Exposed Children Trial |
Condition: |
 |
Lead Exposure |
Intervention: |
 |
 |
 |
22 |
 |
Completed |
 |
Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) |
Conditions: |
 |
Beta Thalassemia;  Hemoglobinopathy |
Intervention: |
 |
Drug:Â Hydroxyurea |
 |
23 |
 |
Completed |
 |
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia |
Condition: |
 |
Beta Thalassemia |
Intervention: |
 |
Drug:Â 5-Azacytidine |
 |
24 |
 |
Completed |
 |
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis |
Conditions: |
 |
Anemia (Iron-Loading);  Beta-Thalassemia;  Hematologic Diseases;  Hemoglobinopathies;  Thalassemia;  Iron Overload;  Hemochromatosis |
Intervention: |
 |
Drug:Â deferoxamine |
 |
25 |
 |
Completed |
 |
Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN) |
Conditions: |
 |
Anemia, Cooley’s;  Beta-Thalassemia;  Hematologic Diseases;  Thalassemia;  Osteoporosis;  Iron Overload;  Hypertension, Pulmonary |
Interventions: |
 |
Drug:Â Deferoxamine; Â Drug:Â Deferiprone; Â Drug:Â Arginine; Â Drug:Â Sildenafil; Â Drug:Â Decitabine |
 |
26 |
 |
Active, not recruiting |
 |
Deferoxamine for the Treatment of Hemochromatosis |
Conditions: |
 |
Diabetes Mellitus;  Heart Disease;  Hemochromatosis;  Thalassemia |
Intervention: |
 |
 |
 |
27 |
 |
Completed |
 |
Monoclonal Antibody Therapy in Treating Patients With Leukemia |
Conditions: |
 |
Lymphoma;  Radiation Toxicity |
Interventions: |
 |
Drug: pentetic acid calcium;  Drug: yttrium Y 90 daclizumab;  Procedure: monoclonal antibody therapy;  Procedure: radioimmunotherapy;  Procedure: radioprotection |
 |
28 |
 |
Completed |
 |
Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions |
Condition: |
 |
Beta-Thalassemia |
Interventions: |
 |
Drug:Â ICL670; Â Drug:Â deferoxamine |
 |
29 |
 |
Completed |
 |
Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias |
Conditions: |
 |
Beta-Thalassemia;  Myelodysplastic Syndromes;  Fanconi Syndrome;  Anemia, Diamond-Blackfan;  Anemia, Aplastic |
Intervention: |
 |
Drug:Â Deferasirox |
 |
30 |
 |
Completed |
 |
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions |
Condition: |
 |
Anemia, Sickle Cell |
Interventions: |
 |
Drug:Â ICL670; Â Drug:Â deferoxamine |
 |
31 |
 |
Active, not recruiting |
 |
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients |
Conditions: |
 |
Sickle Cell Disease;  Iron Overload;  Hemolytic Anemia |
Intervention: |
 |
Drug:Â Deferasirox |
 |
32 |
 |
Active, not recruiting |
 |
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients |
Conditions: |
 |
Myelodysplastic Syndromes;  Iron Overload |
Intervention: |
 |
Drug:Â deferasirox |
 |
33 |
 |
Completed |
 |
Chromium Picolinate for the Treatment of Metabolic Syndrome |
Conditions: |
 |
Metabolic Syndrome X;  Prediabetic State;  Insulin Resistance;  Obesity;  Metabolic Diseases |
Intervention: |
 |
Drug: Chromium picolinate |
 |
34 |
 |
Completed |
 |
A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis |
Conditions: |
 |
Beta-Thalassemia; Â Hemosiderosis |
Intervention: |
 |
Drug:Â deferasirox |
 |
35 |
 |
Active, not recruiting |
 |
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload |
Conditions: |
 |
Thalassemia;  Sickle Cell Disease;  Diamond Blackfan Anemia;  Myelofibrosis |
Intervention: |
 |
Drug:Â Deferasirox |
 |
36 |
 |
Completed |
 |
Chromium and Insulin Action |
Condition: |
 |
Type 2 Diabetes |
Intervention: |
 |
Drug: Chromium Picolinate |
 |
37 |
 |
Completed |
 |
Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM |
Condition: |
 |
Diabetes Mellitus, Type 2 |
Intervention: |
 |
Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg) |
 |
38 |
 |
Completed |
 |
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-Dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine |
Conditions: |
 |
Diphtheria;  Tetanus;  Pertussis;  Hepatitis B;  Poliomyelitis;  Hib Disease |
Interventions: |
 |
Biological: Pertussis vaccine;  Biological: DTPa-HBV-IPV/Hib |
 |
39 |
 |
Completed |
 |
A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM |
Condition: |
 |
Diabetes Mellitus, Type 2 |
Intervention: |
 |
Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg) |
 |
40 |
 |
Completed |
 |
Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules |
Conditions: |
 |
Healthy; Â Infant |
Intervention: |
 |
Biological: DTPa-HBV-IPV/Hib vaccine |
 |
41 |
 |
Completed |
 |
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants |
Conditions: |
 |
Diphtheria;  Tetanus;  Pertussis;  Hepatitis B;  Poliomyelitis;  Haemophilus Influenza Type b Disease |
Intervention: |
 |
Biological: DTPa-HBV-IPV/Hib vaccine |
 |
42 |
 |
Active, not recruiting |
 |
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine |
Conditions: |
 |
Healthy; Â Infant |
Intervention: |
 |
Biological: DTPa-HBV-IPV/Hib vaccine |
 |
43 |
 |
Terminated |
 |
Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes |
Condition: |
 |
Type 2 Diabetes |
Intervention: |
 |
Drug: Chromium Picolinate |
 |
44 |
 |
Active, not recruiting |
 |
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients |
Condition: |
 |
Hemochromatosis |
Interventions: |
 |
Drug: Deferiprone (L1);  Drug: Desferrioxamine |
 |
45 |
 |
Active, not recruiting |
 |
Iron-Fortified Whole Maize Flour Trial |
Condition: |
 |
Anaemia |
Intervention: |
 |
Drug: NaFeEDTA, Electrolytic Iron |
 |
46 |
 |
Completed |
 |
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers |
Condition: |
 |
Healthy |
Interventions: |
 |
Drug:Â Deferasirox; Â Drug:Â Rifampicin |
 |
47 |
 |
Active, not recruiting |
 |
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam |
Condition: |
 |
Healthy |
Intervention: |
 |
Drug:Â Deferasirox |
 |
48 |
 |
Active, not recruiting |
 |
Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA |
Conditions: |
 |
Central Nervous System Tumors;  Brain Tumors |
Interventions: |
 |
Drug:Â Gallium-67Â Citrate; Â Drug:Â In-111Â DTPA |
 |
49 |
 |
Completed |
 |
Effects of Chromium Picolinate on Food Intake |
Conditions: |
 |
Obesity;  Atypical Depression |
Intervention: |
 |
Drug: Chromium Picolinate |
 |
50 |
 |
Completed |
 |
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients |
Condition: |
 |
HIVÂ Infections |
Intervention: |
 |
Drug: Ditiocarb sodium |